Conditions: Cerebrovascular Accident
Allocation:  | Intervention model: PARALLEL
Enrollment: 1295
Healthy volunteers: no

Brief summary:
Phase III study to compare the preventive effect of recurrent brain infarction and safety of Aggrenox (combination drug containing sustained-release dipyridamole 200 mg/acetylsalicylic acid 25 mg) twice daily vs. acetylsalicylic acid 81 mg once daily

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Aggrenox capsule intervention 2: Acetylsalicylic Acid (ASA)
Intervention descriptions: intervention 1: extended-release dipyridamole 200 mg plus ASA 50 mg in a capsule, 2 capsules twice daily intervention 2: Acetylsalicylic Acid (ASA) 81 mg, 1 tablet once daily

Protocol document: